PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis
Authors:
- Kallesh D. JayappaKJKallesh D. Jayappa
- Brian TranBTBrian Tran
- Vicki L. GordonVGVicki L. Gordon
- Shekhar SahaSSShekhar Saha
- Caroline C. FarringtonCFCaroline C. Farrington
- Caitlin M. O’cOnnorCOCaitlin M. O’cOnnor
- Krista M. IsaacKIKrista M. Isaac
- Mark KesterMKMark Kester
- Timothy P. BenderTBTimothy P. Bender
- Michael E. WilliamsMWMichael E. Williams
Open Access
- 3 July 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (13)
Abstract
Targeted therapies such as venetoclax (VEN) (Bcl-2 inhibitor) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). We previously reported that persister CLL cells in treated patients overexpress multiple antiapoptotic proteins and display resistance to proapoptotic agents. Here, we demonstrated that multidrug-resistant CLL cells in vivo exhibited apoptosis restriction at a pre-mitochondrial level due to insufficient activation of the Bax and Bak (Bax/Bak) proteins. Co-immunoprecipitation analyses with selective BH domain antagonists revealed that the pleiotropic proapoptotic protein (Bim) was prevented from activating Bax/Bak by “switching” interactions to other upregulated antiapoptotic proteins (Mcl-1, Bcl-xL, Bcl-2). Hence, treatments that bypass Bax/Bak restriction are required to deplete these resistant cells in patients. Protein phosphatase 2A (PP2A) contributes to oncogenesis and treatment resistance. We observed that small-molecule activator of PP2A (SMAP) induced cytotoxicity in multiple cancer cell lines and CLL samples, including multidrug-resistant leukemia and lymphoma cells. The SMAP (DT-061) activated apoptosis in multidrug-resistant CLL cells through induction of mitochondrial permeability transition pores, independent of Bax/Bak. DT-061 inhibited the growth of wild-type and Bax/Bak double-knockout, multidrug-resistant CLL cells in a xenograft mouse model. Collectively, we discovered multidrug-resistant CLL cells in patients and validated a pharmacologically tractable pathway to deplete this reservoir.Keywords
This publication has 79 references indexed in Scilit:
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisionsCancer Letters, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Is mPTP the gatekeeper for necrosis, apoptosis, or both?Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemiaBlood, 2011
- Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative ChemotherapyDigestive Diseases and Sciences, 2010
- Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytesCell Death & Differentiation, 2010
- Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transitionProceedings of the National Academy of Sciences, 2009
- Bad Targets the Permeability Transition Pore Independent of Bax or Bak to Switch between Ca2+-Dependent Cell Survival and DeathMolecular Cell, 2009
- Low Expression of Bax Predicts Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Treated with Definitive ChemoradiotherapyClinical Cancer Research, 2007
- Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacityBlood, 2006